AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05545800
Drug: premixed insulin analogues
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will received twice a day. The total daily insulin dose will be initiated at 0.4-0.5 units/kg/day and adjusted according to the plasma glucose. All groups received counseling on lifestyle modification.
Trial: NCT05616364
Drug: Dexmedetomidine injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine intravenous
Trial: NCT05616364
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol intravenous
Trial: NCT01487278
Drug: misprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mcg misoprostol oral
Trial: NCT00269815
Drug: methylphenidate HCl
RxNorm normalized name: methylphenidate HCl
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02994498
Drug: DCB-BO1301
RxNorm normalized name: DCB
DrugBank: Dichlorobenzene (DB14046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
Trial: NCT04437004
Drug: Fenfluramine
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
Trial: NCT06212648
Drug: SPC1001 High
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Trial: NCT06212648
Drug: SPC1001 Low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Trial: NCT04225429
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800mg/dose taken orally twice every day.
Trial: NCT04856098
Drug: Indacaterol maleate and glycopyrronium bromide
RxNorm normalized name: glycopyrronium / indacaterol
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batch A Ultibro Breezhaler 85/43 μg 2 capsules
Trial: NCT04856098
Drug: Indacaterol maleate and glycopyrronium bromide
RxNorm normalized name: glycopyrronium / indacaterol
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batch A Ultibro Breezhaler 85/43 μg 1 capsule
Trial: NCT04856098
Drug: Indacaterol maleate and glycopyrronium bromide
RxNorm normalized name: glycopyrronium / indacaterol
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batch B Ultibro Breezhaler 85/43 μg 2 capsules
Trial: NCT05411432
Drug: 68Ga labeled HER2 Affibody
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inject the tracer to subjects and perform PET/CT scans
Trial: NCT05742425
Drug: Serplulimab Combined With FOLFIRI and Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
Trial: NCT05391867
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tyrosine kinase inhibitor
Trial: NCT06682884
Drug: Lorlatinib 100 mg
RxNorm normalized name: lorlatinib 100 MG
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients will be registered to receive oral lorlatinib 100mg qd for 6-8 weeks each during the neoadjuvant therapy phase
Trial: NCT05727761
Drug: pioglitazone-metformin
RxNorm normalized name: metformin / pioglitazone
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks
Trial: NCT06482684
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: See description of treatment arms
Trial: NCT06196853
Drug: Aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Give aminophylline for 5 days to keep serum theophylline level 5-15 mg/dl
Trial: NCT05685264
Drug: Ponsegromab
RxNorm normalized name: Ponsegromab
DrugBank: Ponsegromab (DB18943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one subcutaneous injection
Trial: NCT05685264
Drug: Ponsegromab
RxNorm normalized name: Ponsegromab
DrugBank: Ponsegromab (DB18943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive four subcutaneous injections
Trial: NCT04929288
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will complete three experimental sessions. In each session, participants will provide detailed reports of their alcohol consumption over the past five days, and they will provide a blood sample for hormone assays. They will perform tasks during fMRI to assess each of the neurofunctional addiction domains: inhibitory control, negative emotionality, and cue reactivity. Following the fMRI scan, subjects will self-administer intravenous alcohol to provide a controlled assessment of pharmacologically-driven alcohol consumption.
Trial: NCT06081595
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib 100mg bid
Trial: NCT06081595
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 375mg qd
Trial: NCT04982211
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral propranolol hydrochloride capsules, dosed per participant weight
Trial: NCT05787561
Drug: Avutometinib (VS-6766)
RxNorm normalized name: Avutometinib
DrugBank: Avutometinib (DB15254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 mg PO, twice weekly
Trial: NCT05787561
Drug: Defactinib
RxNorm normalized name: Defactinib
DrugBank: Defactinib (DB12282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
Trial: NCT05318924
Drug: Ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
Trial: NCT05673629
Drug: Utidelone Injection in combination with AC
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence.
Trial: NCT05673629
Drug: Docetaxel Injection in combination with AC
RxNorm normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence.
Trial: NCT05468242
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The Bevacizumab was administrated concurrently with neoadjuvant chemo-immunotherapy (7.5mg/kg) once every 3 weeks (Q3W).
Trial: NCT05468242
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
Trial: NCT06585514
Drug: CD19 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Trial: NCT00000881
Drug: Cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000881
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06340984
Drug: Montelukast 10 Mg Oral Tablet
RxNorm normalized name: montelukast 10 MG Oral Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group modrate and severe acne will receive Montelukast therapy , dose: 10mg/day, duration of therapy: three months., Quantitively assay of level of serum intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) in group moderate acne vs group severe acne pre Montelukast treatment and after three months of treatment vs control group
Trial: NCT05887843
Drug: Mometasone + Azelastine
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril
Trial: NCT05887843
Drug: Mometasone Furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril
Trial: NCT05887843
Drug: Azelastine Hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
Trial: NCT00006617
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00006617
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00006617
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00006617
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05697237
Drug: Carrelizumab
RxNorm normalized name: CERTOLIZUMAB
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Carrelizumab 200mg/3 weeks
Trial: NCT05697237
Drug: Solfantinib
RxNorm normalized name: SULFATINIB
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solfantinib 300mg/d
Trial: NCT02534077
Drug: Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
Trial: NCT02534077
Drug: Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
Trial: NCT06320301
Drug: Adebrelimab + GEMOX + TKI
RxNorm normalized name: Hemox A
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab 20 mg/kg, once every 3 weeks (Q3W), maintained for 1 year. The interval between two doses should not be less than 12 days.~Tyrosine kinase inhibitor (TKI) Lenvatinib: 12 mg (3 capsules 4 mg) or 8 mg (2 capsules 4 mg) once daily (QD) at fixed times daily, on an empty stomach or with food; Apatinib: 250mg orally, QD, 5 days of medication, 2 days off (5 on 2 off) or once every other day (QOD), half an hour after meals; Sorafenib: 0.4g (2 × 0.2g) twice or once daily on an empty stomach or with a low-fat or medium-fat diet Anlotinib: 12 mg orally before breakfast, QD. The drug was taken continuously for 2 weeks and stopped for 1 week.~GEMOX: gemcitabine 800mg/m2 and oxaliplatin 85mg/m2, intravenous infusion, D2, D15, D29, until 6 cycles of treatment were completed, or the patients who did not reach 6 cycles had intolerable adverse reactions, then the combination chemotherapy was terminated.
Trial: NCT05220813
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local infiltration by lidocaine in the surgical site
Trial: NCT05220813
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks
Trial: NCT01646593
Drug: Regorafenib (BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg BAY73-4506, 3 weeks on drug, 1 week off
Trial: NCT04984057
Drug: PS is given according to the 2019 European RDS management guideline
RxNorm normalized name: European blueberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS is given according to the 2019 European RDS management guideline
Trial: NCT00016692
Drug: Z-100
RxNorm normalized name: ANZ-100
DrugBank: ANZ-100 (DB05967)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05504486
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet; take once daily; target daily dose of 2 mg
Trial: NCT04988971
Drug: a compound glutamine capsule
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Trial: NCT04725812
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eculizumab Intravenous Solution
Trial: NCT06356194
Drug: Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK
DrugBank: Ruzasvir (DB11713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
Trial: NCT06356194
Drug: Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.
DrugBank: Ruzasvir (DB11713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
Trial: NCT06275594
Drug: Byfavo
RxNorm normalized name: Byfavo
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For induction and maintenance of sedation
Trial: NCT06275594
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For induction and maintenance of sedation
Trial: NCT05862337
Drug: Anlotinib hydrochloride capsules, Penpulimab injection
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.~Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1).
Trial: NCT05862337
Drug: Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control, no active substance.
Trial: NCT06172036
Drug: irinotecan liposome + oxaliplatin + 5-FU / LV
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
Trial: NCT05406115
Drug: AMG 786
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02129751
Drug: bupropion hydrobromide
RxNorm normalized name: Bupropion Hydrobromide
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study drug
Trial: NCT04903353
Drug: Comparison of Risperidone and Aripiprazole
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Comparing two FDA approved medications for treatment of irritability in autism
Trial: NCT05036577
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment.~Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
Trial: NCT05036577
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.
Trial: NCT05036577
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
Trial: NCT05169437
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible participants will receive daily dosing of Niraparib.
Trial: NCT04679012
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.
Trial: NCT05597722
Drug: Amphetamine-Dextroamphetamine
RxNorm normalized name: amphetamine-dextroamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this arm will be prescribed 10mg of amphetamine-dextroamphetamine to take as needed to help with cognitive fog. Participants in this arm will be contacted at 2 and 6 weeks to assess for any side effects from taking the medication.
Trial: NCT04679012
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Trial: NCT04679012
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Trial: NCT04679012
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
Trial: NCT04679012
Drug: Hydroxydaunomycin
RxNorm normalized name: 14-hydroxydaunomycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.